BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19109559)

  • 1. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
    Zalevsky J; Leung IW; Karki S; Chu SY; Zhukovsky EA; Desjarlais JR; Carmichael DF; Lawrence CE
    Blood; 2009 Apr; 113(16):3735-43. PubMed ID: 19109559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
    Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
    Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies.
    Cardarelli PM; Rao-Naik C; Chen S; Huang H; Pham A; Moldovan-Loomis MC; Pan C; Preston B; Passmore D; Liu J; Kuhne MR; Witte A; Blanset D; King DJ
    Cancer Immunol Immunother; 2010 Feb; 59(2):257-65. PubMed ID: 19657637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
    Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
    J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
    Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
    Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
    Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
    Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
    Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
    Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
    Chu SY; Vostiar I; Karki S; Moore GL; Lazar GA; Pong E; Joyce PF; Szymkowski DE; Desjarlais JR
    Mol Immunol; 2008 Sep; 45(15):3926-33. PubMed ID: 18691763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered antibody Fc variants with enhanced effector function.
    Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.
    Liu L; Jacobsen FW; Everds N; Zhuang Y; Yu YB; Li N; Clark D; Nguyen MP; Fort M; Narayanan P; Kim K; Stevenson R; Narhi L; Gunasekaran K; Bussiere JL
    J Biol Chem; 2017 Feb; 292(5):1876-1883. PubMed ID: 27994063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.
    Kellner C; Zhukovsky EA; Pötzke A; Brüggemann M; Schrauder A; Schrappe M; Kneba M; Repp R; Humpe A; Gramatzki M; Peipp M
    Leukemia; 2013 Jul; 27(7):1595-8. PubMed ID: 23277329
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
    Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
    J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.